Background: Aromatase inhibitors (AIs) may promote ovarian function recovery (OFR). True incidence, predictors and impact on the outcome of OFR are unknown.
introduction
According to current clinical guidelines, aromatase inhibitors (AIs) should form a part of adjuvant endocrine therapy in postmenopausal patients with hormone receptor-positive BC. They can be used either as up-front therapy or as sequential treatment after 2-3 or 5 years of tamoxifen [1, 2] . The efficacy of AIs depends on the suppression of serum and tissue levels of E2 [3, 4] and, in contrast to tamoxifen, their therapeutic effect can be abolished in the presence of functional ovaries [5] . After receiving adjuvant chemotherapy, premenopausal women can experience ovarian dysfunction leading to high rates of persistent chemotherapy-induced amenorrhea (CIA) [6] . For these patients, the initiation of adjuvant endocrine treatment with tamoxifen has been recommended. However, incorporating an AI at some point during adjuvant treatment has also been recommended, if pre-or perimenopausal women at the time of diagnosis have become unequivocally postmenopausal in subsequent years [1] . Some of these women may have residual ovarian function, and if treated with an AI may experience a clinical ovarian function recovery (OFR) [7, 8] . Under these circumstances, the incidence and predictive factors for OFR are currently unknown, partly because a correct assessment of ovarian function requires regular monitoring of ovarian markers [9] , and because an accurate and sensitive assay is needed to quantify low levels of E2 during therapy with an AI [10] .
The purpose of this study was to estimate incidence, potential predictive factors and prognosis of OFR in CIA patients switching from tamoxifen to exemestane. The incidence of OFR was estimated via two E2 assays: a highly sensitive immunoassay (indirect method) and a less sensitive assay used routinely in the clinical setting (direct method), for comparison. We also carried out regular biochemical and biophysical tests of ovarian reserve, including such novel markers as serum antimullerian hormone (AMH) levels.
patients and methods

study design
This was a prospective, exploratory study conducted at Instituto Valenciano de Oncología (IVO), Valencia, Spain. It was approved by the local review board, and all participating patients provided informed signed consent.
Eligible patients were early stage, estrogen receptor (ER)-positive BC women on tamoxifen, with CIA for at least 2 years, and E2 values (by direct assay) in the postmenopausal range (<146 pmol/l). These patients, while on tamoxifen, underwent a full assessment of ovarian function just before switching to exemestane (baseline). Subsequent assessments of ovarian function were carried out at months 1, 3 and 6 of exemestane treatment. Exemestane was stopped if menses or biochemical OFR (by direct assay) occurred, and tamoxifen treatment was restarted.
ovarian function assessments • menses: participants were asked to report immediately if they experienced any menstrual bleeding; if so a blood sample was obtained to measure E2 and FSH levels.
• serum E2 levels, measured by two methods:
At IVO by a microparticle enzyme immunoassay (MEIA) in a AxSYM System Abbot®. The sensitivity of the assay was calculated to be 73.4 pmol/l based on the 95th percentile (n = 40 runs in replicates of 10) of AxSYM Estradiol Calibrator A rates (0 pmol/l). This represents the lowest concentration of E2 that can be distinguished from zero. The within-assay coefficient of variation was 14.8%. The postmenopausal reference value was <146 pmol/l. 2) indirect immunoassay (extraction-based).
At Royal Marsden Hospital, London, UK, using a sensitive radioimmunoassay after organic extraction with diethyl ether [11, 12] . The extraction step removes substances potentially interfering with the immunoassay, particularly cross-reacting water-soluble steroid conjugates. The degree of cross reaction with exemestane has been reported to be very low (<3.0 pmol/l; unpublished observation by Royal Marsden research laboratory).The sensitivity of the assay was defined as 3 pmol/l by calculation from the 95% confidence limits of the zero standard. Within-assay variability, assessed in 16 assays using four (0.20 ml) replicates of a serum pool per assay (32 pmol/l), was 5.6%. The between-assay coefficient of variation for the same pool was 9.4%. The postmenopausal reference value was <60 pmol/l.
• follicle stimulating hormone (FSH): At IVO by MEIA in a AxSYM System Abbot®. The sensitivity of the assay was calculated to be 0.37 mIU/ml based on the 95th percentile (n = 720 runs in replicates of 10) of AxSYM FSHl Calibrator A rates (0 mIU/ml), and represents the lowest concentration of FSH that can be distinguished from zero. The withinassay coefficient of variation was 4.89%, and the between-run coefficient of variation was 2.25%. The postmenopausal reference value was >26 mIU/ml.
• antimullerian hormone (AMH): At IVO by AMH gen II enzyme-linked immunosorbent assay (Diagnostic System Laboratories®). The lowest amount of AMH in a sample which could be detected with a 95% probability was 0.08 ng/ml. The value was determined by processing a complete seven-point calibration curve, controls and seven serum samples in the range of zero-1.5 ng/ml. Two assay runs per day were carried out over 10 days, with all samples run in duplicate per run. The within-run coefficient of variation was 4.025 (range 4-5.6), and the between-run coefficient of variation was 4.625 (range 4-5.6). Calibrator controls and samples were carried out in duplicate. The postmenopausal reference value was <0.08 ng/ml.
• vaginal ultrasound: An ultrasound examination was carried out on the same day that blood samples were obtained by the same radiologist to determine: 1) antral follicle count (AFC): the follicles visualized and counted were 2-10 mm in size, round-or oval-shaped echo-free structures. The numbers of follicles in both ovaries were summed for the total AFC. 2) ovarian volume (OV): calculated for each ovary using the formula OV = D1 × D2 × D3 × π/6, where D1, D2 and D3 are maximal perpendicular diameters of the ovary. 3) endometrial thickness.
definition of OFR
Ovarian function was considered to have returned when any of the following events occurred:
• Resumption of menses.
• E2 levels inconsistent with postmenopausal women on AI (indirect: >8 pmol/l; direct: >165 pmol/l) PLUS premenopausal FSH levels (<26 IU/l).
• Clearly non-postmenopausal E2 values (indirect >55 pmol/l; direct >220 pmol/l).
If menses and biochemical OFR occurred simultaneously, only menstruation was recorded as the event.
statistical methods
On the assumption that the rate of OFR assessed by a clinical E2 assay could be 25% [7] , a sample size of 50 patients was required to estimate incidence of OFR with a precision of 12% and a CI of 95%. Baseline demographics and characteristics of the patient cohort were summarized using mean, standard deviation (SD) and range for continuous variables and percentage for discrete variables. Time-to-event data were summarized using the Kaplan-Meier method and compared using the log-rank test. We defined disease-free survival (DFS) as the time between the first day of treatment with exemestane and the date of breast cancer progressive disease or death. Baseline parameter values were compared between patients with and without OFR using unpaired Student's t-test for continuous variables and Pearson's chi-square test for categorical variables. Whenever parameter levels below the sensitivity limits of the assays were found, the corresponding sensitivity limit was used for statistical analysis. By receiver operating characteristic (ROC) analysis, the optimal cut-off for age at the start of exemestane treatment was evaluated in predicting OFR. A multivariate analysis of potential baseline predictive factors of OFR was carried out using a logistic regression model. All of the reported significance levels are two-sided, and P < 0.05 was considered to represent a significant correlation. Table 1 . Only one patient had irregular menses before chemotherapy; all of them were treated with adjuvant chemotherapy (75% anthracyclines plus taxanes) and had subsequent CIA. The median age at the start of exemestane treatment was 48 years (41-55), with a median time of amenorrhea of 2.5 years (range 2-4.5 years). As expected, the mean baseline E2 levels measured by a direct assay were significantly higher than that by an indirect assay (77.7 versus 26.6 pmol/l, P < 0.0001). AMH levels were below the range of detection in all patients but one. Ten patients (19%) had at least one antral follicle.
incidence and time to OFR Table S1 , available at Annals of Oncology online). The median time to OFR did not differ according to which type of assay was used to measure E2; 5.4 months (95% CI 1.2-9.6) by indirect assay and 6.0 months (95% CI 4.8-7.1) by direct assay.
baseline characteristics and incidence of OFR
Association between baseline patient characteristics and incidence of OFR is shown in Table 2 . The mean age was the only baseline marker differing between patients with or without OFR (46.0 versus 49.3 years, P < 0.0001). According to an ROC analysis, age <48 years at the start of exemestane treatment predicted OFR (sensitivity: 59%; 1-specificity: 17%; AUC 0.796; P = 0.001). In patients <48 years (n = 28), the rate of OFR was 50%, and for patients >50 years it was 12% (chi-square, P = 0.005). When E2 was measured by an indirect assay, there was a trend towards higher baseline E2 levels in patients who had OFR compared with those without OFR (mean baseline E2 levels 34.2 versus 23.4 pmol/l, P = 0.08). In multivariate logistic regression analysis [including age at the start of exemestane treatment, time of amenorrhea, E2 baseline levels by indirect and direct assays, baseline FSH levels, baseline ovarian volume, presence of antral follicles and body mass index (BMI)], the risk of OFR was associated only with young age at the start of exemestane treatment (OR 0.44; 95% CI 0.24-0.78, P = 0.006). Increased E2 baseline levels measured by the indirect assay showed a marginal association with OFR (OR 1.07; 95% CI 0.99-1.15, P = 0.06) ( Table 3) .
longitudinal assessments of ovarian function
At each time interval, mean E2 (by indirect assay) was significantly higher in patients who had OFR compared with those who did not (month 1: 105 versus 5.53 pmol/l; month 
discussion
Around 40%-90% of BC patients who undergo adjuvant chemotherapy experience amenorrhea. Within 1 year after chemotherapy completion, some patients can recover from menses spontaneously depending on the age, type of chemotherapy (more frequent with anthracycline regimens than with combination chemotherapy with cyclophosphamide, methotrexate and fluorouracil) and tamoxifen use [6, 13] . Menopausal status is a major factor to be taken into account when prescribing endocrine therapy. In patients with treatment-related amenorrhea, the menopausal status is ambiguous and difficult to establish. Prolonged amenorrhea in itself is not synonymous with menopause [6] . In addition, although in natural menopause elevated FSH and reduced E2 levels are suggestive of menopause, in patients taking tamoxifen, these biomarkers are not reliable. Tamoxifen interacts with the pituitary axis decreasing FSH but maintaining E2 levels [14, 15] contributing in this way to persistent amenorrhea in 15% of women after chemotherapy [13] .
Previous clinical reports have suggested that there may be a possibility of late recovery of ovarian function among women with CIA during AI therapy [7, 8] . Our study is the first to address this issue prospectively by performing complete and exhaustive ovarian monitoring. We have been able to show that We also hypothesized that the incidence of OFR could be different depending on the methodology used to measure E2 levels. Mass spectrometry is considered as a reference standard for measuring serum E2 levels, but is not practical for widespread use. Two other methods used are indirect and direct immunoassays. It has been reported that commercially available methods (direct methods) lack accuracy and sensitivity and could lead to inaccurate results in the assessment of postmenopausal E2 levels [10] . An indirect method, involving a purification step before radioimmunoassay, has been proposed as a preferable way to measure low E2 levels [11] . Contrary to our expectation, we found that E2 measurements made using either indirect or direct assays were associated with a similar incidence of OFR (32 versus 30%) and time to OFR (5.4 versus 6.0 months). However, baseline E2 levels assessed by the indirect method could be of interest as a predictive marker of OFR. We found a trend towards higher baseline E2 levels in women who had OFR compared with those who did not (34.4 versus 23.4 pmol/ l, P = 0.08); in contrast, baseline E2 assessed by the direct method was not predictive of OFR.
Age was the only baseline marker clearly associated with OFR. The higher follicular reserve associated with younger age could explain the high incidence of OFR in younger women. Hence, in tamoxifen-treated patients with prolonged amenorrhea, where gonadotropin levels are unsuitable for the determination of menopausal status, age and a sensitive baseline determination of E2 may help to identify candidate patients unsuitable for switching from tamoxifen to an AI.
We also evaluated the role of AMH and antral follicle count (AFC) as predictors of OFR. AMH has been proposed, in the fertility setting, as the most reliable predictor of ovarian aging. AMH levels appear to reflect the quantity of the ovarian follicle pool [16] . The levels decrease with age and are undetectable in the postmenopausal period [17, 18] . In our study, neither AMH nor AFC were helpful in estimating the probability of OFR: baseline levels of AMH were below the range of detection (0.08 ng/ml) in 52/53 patients and remained undetectable in all cases during follow-up. Previous studies in young BC patients have also shown that undetectable AMH levels do not exclude OFR if treated with an AI [19] and that, in many patients, AMH levels remain undetectable after chemotherapy for both amenorrheic and menstruating women [20] . These results confirm that AMH is not a good marker of residual endocrine ovarian function.
Third-generation AIs suppress E2 synthesis by 97%-99%, resulting in a marked reduction in circulating E2, with levels below the normal range of detection [3, 21] . In our study, as shown in Figure 1 , patients who recovered OFR had higher levels of serum E2 compared with those who did not; however even for those patients without OFR, their E2 levels during AI therapy were higher than E2 levels measured in women >60 years on an AI (5.76 versus 3.49 pmol/l, P < 0.05). The degree of E2 suppression needed to achieve clinical benefit remains unclear, but we were able to show that a recovery of ovarian function, during AI treatment, is associated with an increased risk of relapse. This finding suggests that AIs should not be offered to patients with an uncertain menopause status, particularly in those <48 years of age.
In large clinical trials, age has not been clearly associated with the efficacy of AIs. In most studies on adjuvant AIs, women were required to be postmenopausal for eligibility, and the median patient age ranged from 61 to 64 years, which indicates that few patients with potential residual ovarian function had been exposed to an AI. However, the MA.17 trial, which studied the efficacy of 5 years of letrozole therapy following completion of 5 years of tamoxifen therapy, included 889 women who were premenopausal at the time of their breast cancer diagnosis but who became menopausal during the tamoxifen therapy. The median age at diagnosis of premenopausal women was 45 years, and most patients (80%) received chemotherapy. In a subgroup analysis, the women who were premenopausal before treatment experienced a greater benefit from extended letrozole than those who were postmenopausal [22] . This is not contradictory to our results, because women from MA.17 trial who were premenopausal initially were estimated to be in their fifties when letrozole was started, and we report very low incidence of OFR in CIA patients >50 years.
In summary, irrespective of the E2 assay used, there is a high incidence (32%) of OFR in patients with CIA who switch from tamoxifen to exemestane, particularly in women <48 years. In such women, our results suggest that AI therapy should be avoided, even for those with a clinical and biochemical profile compatible with menopause. Although not statistically significant in our study, baseline E2 levels measured by a sensitive assay could be of help in predicting which patients are in danger of OFR while on AI therapy. This finding should be evaluated in a study with sufficient power to detect differences. disclosure
